Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Net Income From Continuing Operations : ¥156 Mil (TTM As of Jun. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Jiangsu Lianhuan Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Jiangsu Lianhuan Pharmaceutical Co's net income from continuing operations for the three months ended in Jun. 2024 was ¥36 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was ¥156 Mil.

Jiangsu Lianhuan Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Lianhuan Pharmaceutical Co Net Income From Continuing Operations Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

83.25

120.15

139.90

166.44

151.34

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Net Income From Continuing Operations	Get a 7-Day Free Trial															32.64	32.90	50.74	37.00	35.68

Jiangsu Lianhuan Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥156 Mil.

Jiangsu Lianhuan Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Lianhuan Pharmaceutical Co Ltd (SHSE:600513) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 21 Wenfeng Road, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225009

Website

http://www.lhpharma.com

Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs.

Executives

Chu Qing Song	senior management
Xia Chun Lai	Director
Pan He Ping	Directors, senior managers
Niu Ben	senior management
Wu Wen Ge	Director
Zhu Yong Jun	senior management
Qian Zhen Hua	Director
Shen Yi	senior management
Huang Wen Tao	senior management
Zhou Jun	senior management
Tu Bin	senior management
Qin Xiong Jian	senior management

Jiangsu Lianhuan Pharmaceutical Co Headlines

No Headlines